Senior FDA Staff Has Final Say Over Disputes In Enzi/Kennedy Drug Safety Bill
Executive Summary
Senior FDA officials will have final say over drug safety disputes under proposed legislation from Sens. Michael Enzi (R-Wyo.) and Edward Kennedy (D-Mass.)
You may also be interested in...
Phase IV Commitments Are Increasingly Delayed, FDA Report Finds
The rate of delayed postmarketing commitments has increased since 2005, according to data provided in FDA's annual "Report on the Performance of Drug and Biologics Firms in Conducting Postmarketing Commitment Studies.
Phase IV Commitments Are Increasingly Delayed, FDA Report Finds
The rate of delayed postmarketing commitments has increased since 2005, according to data provided in FDA's annual "Report on the Performance of Drug and Biologics Firms in Conducting Postmarketing Commitment Studies.
PDUFA IV Is “Golden Opportunity” To Improve Drug Safety Funding And Staff
The current round of reauthorization of the Prescription Drug User Fee Act presents a "golden opportunity" to improve FDA's regulation of drug safety, according to the Institute of Medicine's Assessment of the U.S. Drug Safety System Committee